497 related articles for article (PubMed ID: 28411267)
1. NFE2 Induces miR-423-5p to Promote Gluconeogenesis and Hyperglycemia by Repressing the Hepatic FAM3A-ATP-Akt Pathway.
Yang W; Wang J; Chen Z; Chen J; Meng Y; Chen L; Chang Y; Geng B; Sun L; Dou L; Li J; Guan Y; Cui Q; Yang J
Diabetes; 2017 Jul; 66(7):1819-1832. PubMed ID: 28411267
[TBL] [Abstract][Full Text] [Related]
2. FAM3A activates PI3K p110α/Akt signaling to ameliorate hepatic gluconeogenesis and lipogenesis.
Wang C; Chi Y; Li J; Miao Y; Li S; Su W; Jia S; Chen Z; Du S; Zhang X; Zhou Y; Wu W; Zhu M; Wang Z; Yang H; Xu G; Wang S; Yang J; Guan Y
Hepatology; 2014 May; 59(5):1779-90. PubMed ID: 24806753
[TBL] [Abstract][Full Text] [Related]
3. Exercise induced improvements in insulin sensitivity are concurrent with reduced NFE2/miR-432-5p and increased FAM3A.
Zhang Y; Wan J; Liu S; Hua T; Sun Q
Life Sci; 2018 Aug; 207():23-29. PubMed ID: 29802941
[TBL] [Abstract][Full Text] [Related]
4. Long Noncoding RNA lncSHGL Recruits hnRNPA1 to Suppress Hepatic Gluconeogenesis and Lipogenesis.
Wang J; Yang W; Chen Z; Chen J; Meng Y; Feng B; Sun L; Dou L; Li J; Cui Q; Yang J
Diabetes; 2018 Apr; 67(4):581-593. PubMed ID: 29382663
[TBL] [Abstract][Full Text] [Related]
5. Hepatic Activation of the FAM3C-HSF1-CaM Pathway Attenuates Hyperglycemia of Obese Diabetic Mice.
Chen Z; Ding L; Yang W; Wang J; Chen L; Chang Y; Geng B; Cui Q; Guan Y; Yang J
Diabetes; 2017 May; 66(5):1185-1197. PubMed ID: 28246289
[TBL] [Abstract][Full Text] [Related]
6. FAM3 gene family: A promising therapeutical target for NAFLD and type 2 diabetes.
Zhang X; Yang W; Wang J; Meng Y; Guan Y; Yang J
Metabolism; 2018 Apr; 81():71-82. PubMed ID: 29221790
[TBL] [Abstract][Full Text] [Related]
7. Repurposing Doxepin to Ameliorate Steatosis and Hyperglycemia by Activating FAM3A Signaling Pathway.
Chen Z; Liu X; Luo Y; Wang J; Meng Y; Sun L; Chang Y; Cui Q; Yang J
Diabetes; 2020 Jun; 69(6):1126-1139. PubMed ID: 32312868
[TBL] [Abstract][Full Text] [Related]
8. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease.
Liu X; Chen S; Zhang L
Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E34-E42. PubMed ID: 32228319
[TBL] [Abstract][Full Text] [Related]
9. Dapper1 attenuates hepatic gluconeogenesis and lipogenesis by activating PI3K/Akt signaling.
Kuang JR; Zhang ZH; Leng WL; Lei XT; Liang ZW
Mol Cell Endocrinol; 2017 May; 447():106-115. PubMed ID: 28237722
[TBL] [Abstract][Full Text] [Related]
10. Irisin inhibits hepatic gluconeogenesis and increases glycogen synthesis via the PI3K/Akt pathway in type 2 diabetic mice and hepatocytes.
Liu TY; Shi CX; Gao R; Sun HJ; Xiong XQ; Ding L; Chen Q; Li YH; Wang JJ; Kang YM; Zhu GQ
Clin Sci (Lond); 2015 Nov; 129(10):839-50. PubMed ID: 26201094
[TBL] [Abstract][Full Text] [Related]
11. FAM3A mediates PPARγ's protection in liver ischemia-reperfusion injury by activating Akt survival pathway and repressing inflammation and oxidative stress.
Chen Z; Wang J; Yang W; Chen J; Meng Y; Geng B; Cui Q; Yang J
Oncotarget; 2017 Jul; 8(30):49882-49896. PubMed ID: 28562339
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-185-5p inhibits hepatic gluconeogenesis and reduces fasting blood glucose levels by suppressing G6Pase.
Zheng H; Wan J; Shan Y; Song X; Jin J; Su Q; Chen S; Lu X; Yang J; Li Q; Song Y; Li B
Theranostics; 2021; 11(16):7829-7843. PubMed ID: 34335967
[No Abstract] [Full Text] [Related]
13. FAM3A enhances adipogenesis of 3T3-L1 preadipocytes via activation of ATP-P2 receptor-Akt signaling pathway.
Chi Y; Li J; Li N; Chen Z; Ma L; Peng W; Pan X; Li M; Yu W; He X; Geng B; Cui Q; Liu Y; Yang J
Oncotarget; 2017 Jul; 8(28):45862-45873. PubMed ID: 28515350
[TBL] [Abstract][Full Text] [Related]
14. Decreased lipid metabolism but increased FA biosynthesis are coupled with changes in liver microRNAs in obese subjects with NAFLD.
Latorre J; Moreno-Navarrete JM; Mercader JM; Sabater M; Rovira Ò; Gironès J; Ricart W; Fernández-Real JM; Ortega FJ
Int J Obes (Lond); 2017 Apr; 41(4):620-630. PubMed ID: 28119530
[TBL] [Abstract][Full Text] [Related]
15. Hepatic overexpression of ATP synthase β subunit activates PI3K/Akt pathway to ameliorate hyperglycemia of diabetic mice.
Wang C; Chen Z; Li S; Zhang Y; Jia S; Li J; Chi Y; Miao Y; Guan Y; Yang J
Diabetes; 2014 Mar; 63(3):947-59. PubMed ID: 24296716
[TBL] [Abstract][Full Text] [Related]
16. Imipramine activates FAM3A-FOXA2-CPT2 pathway to ameliorate hepatic steatosis.
Liu X; Hou S; Xiang R; Hu C; Chen Z; Li N; Yan H; Yu X; Li X; Chi Y; Yang J
Metabolism; 2022 Nov; 136():155292. PubMed ID: 35995281
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-451 Negatively Regulates Hepatic Glucose Production and Glucose Homeostasis by Targeting Glycerol Kinase-Mediated Gluconeogenesis.
Zhuo S; Yang M; Zhao Y; Chen X; Zhang F; Li N; Yao P; Zhu T; Mei H; Wang S; Li Y; Chen S; Le Y
Diabetes; 2016 Nov; 65(11):3276-3288. PubMed ID: 27495223
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-206 prevents hepatosteatosis and hyperglycemia by facilitating insulin signaling and impairing lipogenesis.
Wu H; Zhang T; Pan F; Steer CJ; Li Z; Chen X; Song G
J Hepatol; 2017 Apr; 66(4):816-824. PubMed ID: 28025059
[TBL] [Abstract][Full Text] [Related]
19. Regulation of insulin resistance by targeting the insulin-like growth factor 1 receptor with microRNA-122-5p in hepatic cells.
Dong L; Hou X; Liu F; Tao H; Zhang Y; Zhao H; Song G
Cell Biol Int; 2019 May; 43(5):553-564. PubMed ID: 30958584
[TBL] [Abstract][Full Text] [Related]
20. MiR-542-5p Inhibits Hyperglycemia and Hyperlipoidemia by Targeting FOXO1 in the Liver.
Tian F; Ying HM; Wang YY; Cheng BN; Chen J
Yonsei Med J; 2020 Sep; 61(9):780-788. PubMed ID: 32882762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
